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Abstract
Background: Despite hVISA infections being associated with vancomycin treatment failure, no previous study has been able
to detect a mortality difference between heteroresistant vancomycin intermediate Staphylococcus aureus (hVISA) and
vancomycin susceptible Staphylococcus aureus (VSSA) bloodstream infections (BSI).
Methodology: Consecutive methicillin-resistant S. aureus (MRSA) BSI episodes between 1996 and 2008 were reviewed.
Patient demographics, clinical presentation, treatment and overall mortality at 30 days were extracted from the medical
records. All isolates underwent vancomycin minimum inhibitory concentration (VMIC) testing by broth microdilution and
Etest. hVISA was confirmed by population analysis profiling using the area under the curve method (PAP-AUC).
Principal Findings: 401 evaluable MRSA BSI episodes were identified over the 12 years. Of these, 46 (11.5%) and 2 (0.5%)
were confirmed as hVISA and VISA by PAP-AUC respectively. hVISA predominantly occurred in ST239-like MRSA isolates with
high VMIC (2 mg/L). Compared to VSSA, hVISA was associated with chronic renal failure (p,0.001), device related infections
(haemodialysis access) (p,0.001) and previous vancomycin usage (p=0.004). On multivariate analysis, independent
predictors of mortality included age, presence of multiple co-morbidities, principal diagnosis, transit to ICU and severity of
illness while infection related surgery and hVISA phenotype were associated with increased survival.
Conclusions/Significance: The presence of hVISA is dependent on the appropriate interplay between host and pathogen
factors. hVISA in ST239 MRSA is an independent predictor of survival. Whether these findings would be replicated across all
MRSA clones is unknown and warrants further study.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) accounts for
approximately 24% of all S. aureus blood stream infections (BSI) in
Australia. Not only do these infections lead to significant morbidity
and increased health-care costs, they are associated with 30 day
mortality rates of approximately 30% [1,2].
Vancomycin has been regarded as the mainstay of treatment for
these infections [3]. The first isolates with reduced or intermediate
vancomycin (VISA) susceptibility emerged in Japan in 1997 [4].
Shortly thereafter, a heteroresistant vancomycin Staphylococcus
aureus (hVISA) phenotype was detected [5]. hVISA isolates are
characterised by the presence of a resistant subpopulation typically
at a rate of 1 in 10
5 organisms and represents the intermediary
stage between fully vancomycin susceptible S. aureus (VSSA) and
VISA isolates.
hVISA and VISA isolates have since been recognized globally
[6,7]. However, the exact prevalence of hVISA remains difficult to
ascertain as testing methodologies are not standardised. Using the
currently accepted gold standard, population analysis profiling –
area under the curve method (PAP-AUC), hVISA accounts for
between 8 and 29% of all MRSA BSI episodes [6,8].
The clinical significance of hVISA infections remains unclear
[7]. In several retrospective studies, hVISA BSI was associated
with higher rates of vancomycin treatment failure, longer duration
of bacteraemia and high inocula infections such as infective
endocarditis [9,10,11]. In vitro, the presence of heteroresistance is
linked to an isolate’s vancomycin minimum inhibitory concentra-
tion (MIC); principally occurring in MRSA isolates with
MIC $2 mg/L by E-test [12]. The significance of this association
is suggested by several recent studies that demonstrate poorer
outcomes (mortality) in patients with high MIC ($2 mg/L)
MRSA blood stream infections [12,13,14].
Despite all these associations, no study to date has been able to
demonstrate a mortality difference between VSSA and hVISA BSI
[7]. This may suggest reduced virulence of heteroresistance as
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responses [15,16,17]. Indirectly supporting this hypothesis is the
reduced ability of hVISA to cause infection compared to VSSA
isolates [18] and the lower risk of shock with high MIC (2 mg/L)
bacteraemia episodes [13].
The aim of the current study is to correlate vancomycin
susceptibility determined by PAP-AUC, and vancomycin MIC to
morbidity and mortality of MRSA BSI. (This work has been
presented in part at the 50
th Interscience Conference on
Antimicrobial Agents and Chemotherapy [ICAAC], Boston,
MA, 12–15 September, 2010) [19]
Results
During the 12 year period, 409 MRSA bacteraemia episodes
were identified. Eight episodes (1.9%) were excluded due to the
unavailability of the patients’ medical records.
Microbiological characteristics
353 (88%) VSSA; 46 (11.5%) hVISA and 2 (0.5%) VISA
episodes were classified by PAP-AUC from the remaining 401
episodes. An association between increasing vancomycin MIC
(irrespective of method used) and the presence of heteroresistance
existed (Table 1) (p,0.001) with the majority of hVISA (82.6%;
38/46) episodes having a MIC 2 mg/L by broth microdilution.
No evidence of MIC creep was detected over the study period
(data not shown). PFGE was able to categorise 390 (97.3%; 390/
401) episodes with 100% of hVISA isolates resembling ST239-
MRSA-III clone (Table 1).
Clinical characteristics
The two episodes of bacteraemia with VISA were secondary to
a prosthetic joint infection and a post-surgical skin and soft tissue
infection. Both patients were effectively treated with vancomycin,
surgical debridement and several months of oral antibiotics. At 30
days, both patients were alive. Both VISA episodes were excluded
from the remaining analysis. However, all of the subsequent
associations detected between hVISA and VSSA BSI episodes
remained significant if VISA episodes were included and con-
sidered as hVISA.
Clinical characteristics of hVISA compared to VSSA episodes
are shown in Table 2. Patient demographics, mode of acquisition,
location of the original blood culture and severity of illness
(APACHE II score) did not differ between the two groups. hVISA
episodes were significantly more likely to be associated with
patients on dialysis for chronic renal failure (p,0.001) and be
secondary to a haemodialysis access device (p,0.001 vs. p=0.26
for all other principle diagnoses) compared to VSSA patients.
Prior vancomycin therapy (in the preceding 30 days) was more
likely to have occurred in hVISA episodes (p=0.004). In contrast,
there was no difference between the two groups with respect to
antibiotic therapy chosen to treat the current episode, with
vancomycin monotherapy used as the principal therapy in 83.7%
(334/399) of patients. Similarly, vancomycin levels did not differ
between the two groups with the median vancomycin level 12.7
and 14 mg/L for hVISA and VSSA episodes respectively
(p=0.086). No additional differences with respect to patient
management were detected with infection related surgery (21.7%
for hVISA vs. 17.8% for VSSA; p=0.52) or device (line or
haemodialysis access) removal similar in both groups (46.2 &
84.6% for hVISA vs. 57% & 88.6% for VSSA within 2 and 5 days
from the positive blood culture; p=0.31 & 0.57 respectively).
Outcomes
In the 152 episodes (38.1%; 152/399) that had additional blood
cultures performed; hVISA episodes were not more likely to be
persistently bacteraemic (5 of 18; 27.8%) compared to VSSA
episodes (40 of 134; 29.8%). Compared to VSSA, hVISA episodes
had similar rates of metastatic complications but were associated
with longer hospital admissions (an additional 14 days; p=0.033).
Overall mortality at 30 days was 29% (115/401) with hVISA
episodes associated with a significantly lower rate of mortality at 30
days (10.9%) compared to VSSA episodes (31.2%; p=0.003)
(Table 2 and Figure 1). Multiple factors including age, the
presence of congestive cardiac failure, solid organ cancer, transit to
ICU, principle diagnosis, severity of illness (APACHE II score),
lack of infection related surgery and VSSA were all predictors of
mortality at 30 days (Table 3) on univariate analysis. Vancomycin
MIC by E-test or broth microdilution (data not shown) did not
predict mortality in the overall or the vancomycin treated group.
Clonal type by PFGE did not predict outcome (p=0.78).
Independent predictors of mortality in logistic regression
analysis included age (Odds ratio [OR] 1.03 per year; 95%
confidence interval [CI] 1.01–1.05; p=0.005), the presence of
multiple co-morbidities (Charlson weight index; OR 1.24; 95% CI
1.03–1.5; p=0.023), transit to ICU (OR 2.82; 95% CI 1.25–6.35;
Table 1. Microbiological characteristics of Staphylococcus
aureus blood stream infection episodes classified by
population analysis profiling (PAP-AUC).
%hVISA Isolates no. (%)
hVISA (n=46) VSSA (n=353) p-value
Vancomycin MIC
Broth microdilution ,0.001
#0.5 mg/L 2.9 1 (2.2) 34 (9.6)
1 mg/L 1.5 4 (8.7) 270 (76.5)
1.5 mg/L 6.8 3 (6.5) 41 (11.6)
2 mg/L 84.4 38 (82.6) 7(2)
4 mg/L 0.0 0 (0) 1 (0.3)
Etest ,0.001
#0.5 mg/L 0 0 (0) 56 (15.9)
0.75 mg/L 1.3 1 (2.2) 75 (21.2)
1 mg/L 1.9 2 (4.3) 105 (29.7)
1.5 mg/L 10.2 11 (23.9) 97 (27.5)
2 mg/L 60.0 30 (65.2) 20 (5.7)
3 mg/L 100 2 (4.3) 0 (0)
PFGE type
ST239-like* 46 (100) 265 (75.1) 0.025
ST 22-like 0 40 (11.3)
ST 1-like 0 18 (5.1)
ST 93-like 0 10 (2.8)
ST 30-like 0 9 (2.5)
Unclassified 0 11 (3.1)
*Pulse field gel electrophoresis (PFGE) with SmaI restriction. Isolates were
classified based on band characteristics compared to known multilocus
sequence typed isolates.
The proportion of vancomycin susceptible and heteroresistant isolates by
method of minimum inhibitory concentration determination and Pulse Field
Gel Electrophoresis (PFGE) typing.
doi:10.1371/journal.pone.0021217.t001
hVISA
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vancomycin susceptible episodes.
hVISA(n=46) VSSA(n=353) P value
Patient demographics:
Male sex 28 (60.9) 244 (69.1) 0.31
Median Age (IQR in years) 60 (50–70) 60 (50–70) 0.59
Co-morbidities:
Chronic renal failure 20 (43.4) 62 (17.6) ,0.001
Congestive cardiac failure 14 (30.4) 81 (23.0) 0.27
Diabetes 15 (32.6) 97 (27.5) 0.49
Solid organ cancer 8 (17.4) 58 (16.4) 0.83
Haematological malignancy 4 (8.7) 50 (14.2) 0.37
Intravenous Drug Use 1 (2.2) 16 (4.5) 0.71
Recipient of Corticosteroids 7 (15.2) 60 (17.0) 1.0
Mean Charlson Weighted Index (SD) 2.3 (61.5) 2.0 (61.5) 0.12
Mode of acquisition: 0.18
Nosocomial 27 (58.7) 218 (61.8)
Health Care Associated 18 (39.1) 104 (29.5)
Community-acquired 1(2.2) 31 (8.8)
Location of BSI: 0.94
In ICU 10 (21.7) 74 (20.9)
Transit to ICU 4 (8.7) 38 (10.8)
Ward 32 (69.6) 241 (68.3)
Principal diagnosis: 0.006
1
Infective endocarditis 2 (4.3) 13 (3.7)
Skin and Soft Tissue infection 1 (2.2) 31 (8.8)
Osteoarticular infection 3 (6.5) 34 (9.6)
Post-surgical 8 (17.4) 40 (11.3)
Pneumonia 2 (4.3) 50 (14.2)
Device (line related) 9 (19.6) 66 (18.7)
Device (haemodialysis access) 17 (37) 48 (13.6)
Device (Other) 2 (4.3) 21 (5.9)
No focus found 1 (2.2) 39 (11)
Other 1 (2.2) 11 (3.1)
Severity of illness:
Median APACHE II score (IQR) 14 (10–16) 13 (9–18) 0.76
Laboratory parameters
Median C- reactive protein (IQR in mg/L) 167 (101–232) 140 (59–242) 0.51
Median Albumin (IQR in g/L) 31 (20–34) 29 (24–34) 0.75
Antibiotic therapy 0.093
No treatment 2 (4.3) 20 (5.7)
Alternative antibiotic therapy 1 (2.2) 42 (11.9)
Vancomycin as principal therapy 43 (93.4) 291 (82.4)
Vancomycin therapy
Previous vancomycin use 15 (32.6) 54 (15.3) 0.004
Initial vancomycin level (IQR in mg/L) 9.8 (5.9–14) 10.2 (6.5–15.3) 0.40
Median vancomycin level (IQR mg/L) 12.7 (9.9–16) 14 (10.8–17.6) 0.086
Outcomes:
Persistent bacteraemia 5/18 (27.8)* 40/134 (29.8)* 1.0
Metastatic complications 3 (6.5) 12 (3.4) 0.40
Infection related surgery 10 (21.7) 63 (17.8) 0.52
hVISA
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95 CI 1.79–21.5], pneumonia [OR 5.23; 95% CI 2.5–10.9] and
the absence of a identified focus [OR 3.88 95% CI 1.7–8.89];
p,0.001) and severity of illness (APACHE II score; OR 1.11 per
point; 95% CI 1.07–1.15; p,0.001). (Table 4). In contrast, both
hVISA phenotype (OR 0.27; 95% 0.09–0.83; p=0.022) and
infection related surgery (OR 0.27; 95% 0.10–0.74; p=0.011)
were strong predictors of survival while vancomycin MIC did not
predict outcome. The final multivariate model was able to
distinguish between survivors and non-survivors at 30 days with
reasonable accuracy (c-statistic of 0.85) with no evidence of a lack-
of-fit (p=0.91) determined by the Hosmer-Lemeshow test.
Vancomycin MIC was further assessed in vancomycin mono-
therapy treated VSSA episodes only (291 of 353). High
vancomycin MIC (of 2 mg/L by broth microdilution) isolates
had a non-significant lower mortality (22%; 2/9) compared to
episodes with a lower MIC ,2 mg/L (31%; 108/344) (p=0.73).
Discussion
This is one of the largest cohorts of MRSA BSI evaluating
outcomes where all isolates have undergone the gold standard test
(PAP-AUC) for the presence of heteroresistance. Although rates of
hVISA vary widely by geographical region, testing methodology
and study population selected [7]; our rate of 12%, is similar to
two other Australian studies examining consecutive BSI isolates
[9,18]. Prior vancomycin usage was an important risk factor
for the development of heteroresistance while drug exposure;
determined by vancomycin serum trough levels, was not. This is
not surprising as vancomycin trough is a poor surrogate for total
drug exposure [20].
Morbidity was considerable in patients with hVISA infection
with an average increase of hospital stay of 14 days compared to
VSSA episodes. This is despite similar rates of treatment failure,
defined as bacteremic persistence, between the two groups. This
finding supports assertions that hVISA may reflect the conse-
quence rather than the cause of treatment failure [7,21,22]. This
has implications with respect to selecting isolates for further
testing; as PAP-AUC is labour intensive and expensive [21,22]. A
recent review suggested a clinically based algorithm prompted by
persistent bacteraemia [21]. Based on our data, the need to
confirm hVISA phenotype may not be necessary as clinical
management decisions could be determined by the principal
diagnosis and documented treatment failure or bacteraemia
persistence [6,10,21].
Overall 30 day mortality was significantly lower for hVISA
infections (11% vs 31% for VSSA). This may reflect host factors as
hVISA infections were significantly more likely to occur in dialysis
dependent chronic renal failure patients. In addition, device
related infections predominated in hVISA episodes, a principal
diagnosis which generally is associated with better outcomes
especially if the access devices are removed [2].
Independent predictors of mortality included age, presence of
multiple co-morbidities, severity of illness, transit to ICU and
principal diagnosis. All these factors have been previously found to
be associated with increased mortality with transit to ICU a
surrogate marker of severe sepsis [2,13]. However, unlike previous
studies, infection-related surgery was found to be protective. This
variable is strongly confounded by a patients’ ability to undergo a
procedure with the sickest patients excluded from surgery.
However, an alternative explanation is that patients who have
extensive debridement and source control are more likely to
survive due to the increased effectiveness of treatment and
antibiotics [23]. As our data was collected retrospectively, we
were unable to distinguish between these two possibilities.
Nevertheless, given the poor outcomes with MRSA BSI this
intervention should be explored further.
Similarly, contrary to previous studies [9,10,12], the presence of
vancomycin heteroresistance was independently associated with a
decreased 30 day mortality compared to VSSA BSI episodes. The
most likely explanations for these findings are the interplay
between host and pathogen specific factors. MRSA requires an
enduring niche with sustained pressure for hVISA emergence.
However, the propensity for susceptible bacterial populations to
transform to a hVISA phenotype various greatly between MRSA
hVISA(n=46) VSSA(n=353) P value
Median hospital LOS (IQR in days) 45 (19–107) 31 (15–54) 0.033
Overall 30 day mortality 5 (10.9) 110 (31.2) 0.003
2 VISA episodes excluded.
NOTE: Data are no. (%) of episodes, unless otherwise indicated.
1There was a significant difference between the two groups with respect to the principal diagnosis distribution. This difference was due to haemodialysis access device
(p,0.001) with all other diagnoses similar between the 2 groups (p=0.23).
*Only 18 hVISA and 134 VSSA bacteraemia episodes had repeat blood cultures performed, 5 days after the initial isolate.
doi:10.1371/journal.pone.0021217.t002
Table 2. Cont.
Figure 1. Kaplan Meyer survival curves 30 days from the initial
positive blood culture bottle for Methicillin-resistant Staphylo-
coccus aureus. Patients with vancomycin heteroresistance (hVISA) were
significantly less likely to die compared to patients with vancomycin




PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21217Table 3. Univariate analysis of clinical features associated with overall 30 day mortality in Staphylococcus aureus blood stream
infection episodes.
Characteristic Survived (n=284) Died (n=115) P-value
Patient demographics:
Male sex 197 (69.4) 75 (65.2) 0.48
Median Age (IQR in years) 61 (46–72) 72 (64–78) ,0.001
Co-morbidities:
Chronic renal failure 64 (22.5) 18 (15.7) 0.13
Congestive cardiac failure 55 (19.4) 40 (34.8) 0.001
Diabetes 83 (29.2) 29 (25.2) 0.46
Solid organ cancer 48 (16.9) 28 (24.3) 0.011
Haematological malignancy 33 (11.6) 21 (18.3) 0.10
Intravenous Drug Use 16 (5.6) 1 (0.9) 0.030
Recipient of Corticosteroids 45 (15.8) 22 (19.1) 0.46
Mean Charlson Weighted Index (SD) 1.9 (61.5) 2.4 (61.6) 0.004
Mode of acquisition: 0.029
Nosocomial 169 (59.5) 76 (66.1)
Health Care Associated 86 (30.3) 36 (31.3)
Community-acquired 29 (10.2) 3 (2.6)
Location of BSI: 0.004
In ICU 55 (19.4) 29 (25.2)
Transit to ICU 22 (7.7) 20 (17.4)
Ward 207 (72.9) 66 (57.4)
Principal diagnosis: ,0.001
1
Infective endocarditis 6 (2.1) 9 (7.8)
Skin and Soft Tissue infection 27 (9.5) 5 (4.3)
Osteoarticular infection 32 (11.3) 5 (4.3)
Post-surgical 38 (13.4) 10 (8.7)
Pneumonia 20 (7) 32 (27.8)
Device (line related) 62 (21.8) 13 (11.3)
Device (haemodialysis access) 53 (18.7) 12 (10.4)
Device(other) 20 (7) 3 (2.6)
No focus found 21 (7.4) 19 (16.5)
Other 5 (1.8) 7 (6.1)
Severity of illness:
Median APACHE II score (IQR) 12.5 (8–16) 19.1 (13–25) ,0.001
Laboratory parameters:
2
Median Albumin (IQR in g/L) 29.4 (24–34) 27.3 (22–33) 0.017
Antibiotic Therapy:
No treatment 6 (2.1) 39 (33.9) NA
Alternative antibiotic therapy 18 (6.3) 2 (1.7)
Vancomycin as principal therapy 260 (91.5) 74 (64.3)
Vancomycin treated group:
3 0.63
VMIC 1 149 (52.5) 45 (39.1)
VMIC 1.5 72 (25.4) 21 (18.2)
VMIC 2 39 (13.7) 8 (7)
Phenotype:
4 0.003
hVISA by PAP 41 (14.4) 5 (4.3)
VSSA by PAP 243 (85.6) 110 (95.7)
Outcomes:
2
Infection related surgery 64 (22.5) 7 (6.1) ,0.001
Metastatic complications 13 (4.6) 2 (1.7) 0.25
hVISA
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documented to transform and maintain the resistance phenotype
easily and thus is overrepresented (78% of hVISA isolates) in
recent study of MRSA infective endocarditis [6]. These factors
would explain the strong association of hVISA in our chronic renal
failure patients; secondary to the convergence in dialysis units, of
high vancomycin exposed patients and a high MRSA burden.
Moreover, this clarifies the reason for hVISA being limited to the
predominant MRSA hospital clone in our setting, ST239.
Whether these findings would be replicated in similar populations
groups, with other MRSA clones, is unknown and warrants further
study.
Alternatively, our observations support the reduced pathoge-
nicity that may occur with hVISA infections [16,17] and
corroborates the significance of the in vitro genomic alterations in
the major virulence regulator (agr) of vancomycin heteroresistant
S.aureus isolates [24,25]. Additionally, the specificity of hVISA
testing methods vary, Macromethod Etest the most common
method used in BSI studies [12,13] is likely to overestimated the
burden of heteroresistance [22] and thus mask the real effect of
this phenotype.
Given that hVISA episodes occurred predominantly in isolates
with high vancomycin MICs, no association between outcome and
vancomycin MIC was detected. At first glance, this is likewise
contrary to previous studies showing poorer outcomes with high
but susceptible vancomycin MIC bacteremic episodes [12,13,26].
However, our data probably reflects specific ST239 MRSA clonal
issues. Alternatively, as hVISA prevalence varies between
geographical locations [7] with lower rates in non-Oceanic
institutions [6]; MIC data may pertain to VSSA infections only
[12]. Additionally, pathogen factors may play an important role in
determining outcomes in these patients as vancomycin MIC has
been found to be an independent predictor of mortality in
flucloxacillin treated methicillin-sensitive S. aureus episodes. [27].
Irrespective of the differences, our data shows that hVISA or
MIC associations with outcomes are far more complex than first
assumed. There are probably unidentified pathogen specific
factors that direct these responses and that these associations do
not prove causality. Thus it would be prudent to study these issues
further before relegating vancomycin to second line therapy.
This study has several limitations. Data was gathered retro-
spectively. However, as consecutive BSI isolates were examined
over an extended period with a small exclusion rate (2.9%), we
were able to minimise this bias. Furthermore, as clinicians were
unaware of the hVISA status, therapy was not altered based on
presence of heteroresistance and thus adds weight to our findings.
Clinical management could have altered over time with more
aggressive vancomycin dosing, especially in the latter part of
the study leading to a difference. However, no trends, MIC creep
or significant median trough vancomycin levels changes were
detected in our study over time (data not shown). Although the
hVISA sample size is relatively small, our study is the largest
comparative study of hVISA BSI episodes and importantly, uses
the currently accepted gold standard, PAP-AUC, for detection
[21].
Finally, vancomycin tolerance (determined by minimum
bacteriocidal to MIC ratios) was not determined in our study.
As this variable is known to affect vancomycin treatment responses
[28,29] it may have impacted our results. This would be especially
true for VSSA responses as up to 15% of these isolates can be
associated with tolerance and thus suboptimal responses [30].
Conversely hVISA is not exclusively associated with tolerance [30]
and thus this variable warrants further research.
In summary, this study makes several key observations. The
presence of heteroresistance is dependent on the appropriate
interplay between host and pathogen. Factors such as age,
principal diagnosis, presence of co-morbidities, transit to ICU
and severity of illness were all strong predictors of mortality. In
contrast, infection-related surgery and ST239 MRSA hVISA
phenotype were independent predictors of survival. Further studies
are required to validate these findings and tease out the
complexities associated with pathogen specific factors.
Materials and Methods
Setting
Liverpool Hospital, Sydney, Australia is a 600-bed teaching
hospital that provides medical and surgical care to the surrounding
community of approximately 850 000 people.
Microbiological methods
During the 12 year study period, all positive blood cultures
(BacT/ALERT 3DH; bio-Me ´rieux, Australia) with MRSA,
identified according to conventional techniques were stored
(280uC). 458 isolates were identified of which 409 represented
the initial isolate for each episode. Further isolate testing, following
growth on horse blood agar, occurred under blinded conditions
without knowledge of the clinical outcomes. Vancomycin MIC
was determined by E-test using a 0.5 McFarland inoculum (AB
BIODISK, Solna, Sweden) evenly streaked onto Mueller-Hinton
Agar (BBL, Becton Dickinson, MD). Broth microdilution was
performed in accordance with The Clinical Laboratory Standards
Institute method using the current susceptible breakpoint of
#2 mg/L and 4–8 mg/L to define VSSA and VISA isolates
respectively [31]. In addition, all isolates were assessed by PAP-
AUC as previously described [32]. In brief, a bacterial density of
0.5 McFarland was inoculated onto brain heart infusion agar
(BHIA) plates containing increasing doses of vancomycin (0 to
6 ug/ml). Colony counts at 48 hours were plotted against
vancomycin concentration with the AUC calculated. An isolate
2 VISA episodes excluded.
NOTE: Data are no. (%) of patients, unless otherwise indicated.
NA: To prevent survivor treatment bias, analysis of no treatment was not performed.
1The principal diagnosis distribution in deceased patients differed significantly compared to patients that survived. This difference was due to a diagnosis of infective
endocarditis, pneumonia, device (other) related infection and no identifiable focus. The strength of each of these factors can be found in Table 4.
2C-reactive protein and persistent bacteraemia variables were not included in mortality analyses due to a high proportion of missing data.
3The effect of vancomycin MIC determined by E-test on mortality for patients treated with vancomycin. Similar results were obtained for the total group and when MIC
was determined by broth microdilution.
4Heteroresistant vancomycin intermediate (hVISA) and vancomycin susceptible (VSSA) Staphylococcus aureus phenotypes determined using population analysis
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AUC to the reference strain (Mu3; ATCC 700698) was ,0.9; 0.9–
1.3; and .1.3 respectively.
Pulse-field gel electrophoresis
Pulse-field gel electrophoresis (PFGE) with SmaI restriction was
performed on all isolates and analysed as previously described
[33]. Isolates were classified based on band characteristics
compared to known multilocus sequence typed isolates (supplied
by G. Coombs, Royal Perth Hospital, Perth, Western Australia).
Patient selection
All consecutive episodes of MRSA bacteraemia diagnosed
in adult patients (.15 years of age) between 1/1/1996 and the
31/12/2008 were eligible for inclusion in the study. Standard
information was retrospectively obtained from the laboratory
information system and the patients’ clinical records. Patient
demographics (age, sex and admission date), the presence of
co-morbidities, place of onset and location of infection, prin-
ciple diagnosis, need for intensive care and treatments were
extracted. The severity of illness was determined by the
APACHE II score within 48 hrs of the initial obtained blood
culture bottle which subsequently isolated MRSA. Only
antibiotics to which the isolate was sensitive were considered
with the principal antibiotic prescribed for each episode
obtained from the medication charts. Vancomycin usage in
the preceding 30 days was similarly obtained. Glycopeptide
drug levels taken during treatment were retrieved from the
laboratory information system and used to calculate the initial
and median vancomycin levels.
Definitions
A single MRSA BSI episode was defined as one or more
positive blood cultures with systemic manifestations of infection,
such as fever, chills with or without local signs and symptoms.
Bacteraemia episodes were considered to be persistent if the
repeated blood cultures remained positive following 5 days of
appropriate antibiotics (e.g. vancomycin). Co-morbidity was
defined as a pre-existing medical condition present on admission
that could predispose a patient to an infection, for example
diabetes, renal failure requiring dialysis or administration of
immunosuppressive agents within the preceding 30 days. These
were scored using the Charlson weighted index [34]. Bloodstream
infections were considered hospital acquired (HA) when the
positive blood cultures were obtained .48 hours after admission.
The remaining episodes were classified as either community
acquired (CA) or healthcare associated (HCA) based on contact
with the healthcare system within the previous 30 days. The
principal diagnosis was determined using the Centre for Disease
Control definitions [35]. Mortality was defined as death that
occurred within 30 days of the onset of bacteraemia. Attribu-
table mortality was not determined to avoid introducing any
interpretative bias.
Statistical analysis
SAS version 9.2 for Windows (SAS Institute, Cary, NC) and
Stata version 10.1 for Windows (StataCorp LP, College Station,
TX) were used for statistical analysis. Fisher’s Exact Test and
Wilcoxon 2-sample test was used for categorical and continuous
data when appropriate. All-cause mortality at 30 days post-
admission was modelled using logistic regression and survival
analysis. To determine independent predictors of mortality,
vancomycin MIC and variables with a univariate p value ,0.2
were considered a priori to be included in the multivariate model.
A stepwise approach with backwards elimination was then used to
remove statistically non-significant variables until the final ‘‘best’’
model was obtained. CRP and persistent bacteraemia variables
were not included in mortality analyses due to a high proportion of
missing data. Goodness-of-fit of the final logistic models were
assessed using Hosmer-Lemeshow test and c-statistic which
indicates how well the model distinguishes between survivors
and non-survivors where 0.5 indicates a model that is not
predictive and 1.0 indicates a model that predicts perfectly. Only
the clinical and microbiological characteristics associated with the
initial blood stream isolate for each episode were used in the
analysis.
Table 4. Multivariate analysis of risk factors associated with
overall 30 day mortality in Staphylococcus Aureus blood
stream infection episodes.
Risk Factor p-Value Odds Ratio 95% CI
Age, per year 0.005 1.03 1.01–1.05
Co-morbidities:
Chronic renal failure 0.24
Congestive cardiac failure 0.80
Solid organ cancer 0.23
Haematological malignancy 0.45
Intravenous Drug Use 0.47
Charlson Weighted Index 0.023 1.24 1.03–1.50
Mode of acquisition: 0.18
Location of BSI:




Infective endocarditis 6.20 1.79–21.5
Pneumonia 5.23 2.50–10.9
No focus found 3.88 1.70–8.89
Device (other) 3.34 1.15–9.67
Severity of illness:
APACHE II score, per point ,0.001 1.11 1.07–1.15
Laboratory parameters








hVISA by PAP-AUC 0.022 0.27 0.09–0.83
Outcomes:
Infection related surgery 0.011 0.27 0.10–0.74
1Reference group composed of all principle diagnoses with similar 30 day
mortality.
2The effect of vancomycin MIC determined by E-test on mortality for patients
treated with vancomycin. Similar results were obtained for the total group and
when MIC was determined by broth microdilution.
3Heteroresistant vancomycin intermediate (hVISA) Staphylococcus aureus




PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21217Acknowledgments
We would like to thank: J. Mercer, T. Barbagiannakos, D.Chen and M.
Wehrhahn for assistance with laboratory testing.
Author Contributions
Conceived and designed the experiments: SvH IG DP. Analyzed the data:
SvH MJ. Contributed reagents/materials/analysis tools: SvH MJ. Wrote
the paper: SvH MJ IG DP.
References
1. Corey GR (2009) Staphylococcus aureus bloodstream infections: definitions and
treatment. Clin Infect Dis 48 Suppl 4: S254–259.
2. Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, et al. (2009)
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and
New Zealand. Med J Aust 191: 368–373.
3. Chua K, Howden BP (2009) Treating Gram-positive infections: vancomycin
update and the whys, wherefores and evidence base for continuous infusion of
anti-Gram-positive antibiotics. Curr Opin Infect Dis 22: 525–534.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, et al. (1997) Methicillin-
resistant Staphylococcus aureus clinical strain with reduced vancomycin
susceptibility. J Antimicrob Chemother 40: 135–136.
5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, et al. (1997)
Dissemination in Japanese hospitals of strains of Staphylococcus aureus
heterogeneously resistant to vancomycin. Lancet 350: 1670–1673.
6. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, et al. (2009) Heterogeneous
vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-
resistant Staphylococcus aureus isolates from an international cohort of patients
with infective endocarditis: prevalence, genotype, and clinical significance.
J Infect Dis 200: 1355–1366.
7. van Hal SJ, Paterson DL (2011) Systematic Review and Meta-Analysis of the
Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aure-
us Isolates. Antimicrob Agents Chemother 55: 405–410.
8. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, et al. (2008)
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the
metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
J Clin Microbiol 46: 2950–2954.
9. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical
features associated with bacteremia due to heterogeneous vancomycin-
intermediate Staphylococcus aureus. Clin Infect Dis 38: 448–451.
10. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, et al. (2009) Clinical
features of heteroresistant vancomycin-intermediate Staphylococcus aureus
bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect
Dis 199: 619–624.
11. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, et al. (2007) Impact of
reduced vancomycin susceptibility on the therapeutic outcome of MRSA
bloodstream infections. Ann Clin Microbiol Antimicrob 6: 13.
12. Musta AC, Riederer K, Shemes S, Chase P, Jose J, et al. (2009) Vancomycin
MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus
aureus bacteremia: trends over 11 years. J Clin Microbiol 47: 1640–1644.
13. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, et al. (2008) Influence of
vancomycin minimum inhibitory concentration on the treatment of methicillin-
resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46: 193–200.
14. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, et al. (2010)
Clinical characteristics of vancomycin minimum inhibitory concentration of 2
mug/ml methicillin-resistant Staphylococcus aureus strains isolated from
patients with bacteremia. J Infect Chemother.
15. Howden BP, Smith DJ, Mansell A, Johnson PD, Ward PB, et al. (2008) Different
bacterial gene expression patterns and attenuated host immune responses are
associated with the evolution of low-level vancomycin resistance during
persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC
Microbiol 8: 39.
16. McCallum N, Karauzum H, Getzmann R, Bischoff M, Majcherczyk P, et al.
(2006) In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness
cost of teicoplanin resistance. Antimicrob Agents Chemother 50: 2352–2360.
17. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Jr., et al. (2009)
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococ-
cus aureus infection. J Infect Dis 199: 532–536.
18. Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, et al. (2009)
Prospective comparison of the clinical impacts of heterogeneous vancomycin-
intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vanco-
mycin-susceptible MRSA. Antimicrob Agents Chemother 53: 3447–3452.
19. van Hal SJ, Paterson DL, Gosbell IB (2010) The presence of vancomycin
heteroresistance in methicillin-resistant Staphylococcus aureus blood stream
infections is not associated with increased mortality. abstr. K290, p. Abstr 50th
Interscience Conference Antimicrobial Agents and Chemotherapy, Boston, MA.
20. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, et al. (2011)
Vancomycin: We Can’t Get There from Here. Clin Infect Dis 52: 969–974.
21. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (2010) Reduced
vancomycin susceptibility in Staphylococcus aureus, including vancomycin-
intermediate and heterogeneous vancomycin-intermediate strains: resistance
mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev
23: 99–139.
22. van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, et al. (2011)
Performance of Various Testing Methodologies for Detection of Heteroresistant
Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates. J Clin
Microbiol 49: 1489–1494.
23. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ (2003) Impact of valve
surgery on 6-month mortality in adults with complicated, left-sided native valve
endocarditis: a propensity analysis. JAMA 290: 3207–3214.
24. Sakoulas G, Eliopoulos GM, Fowler VG, Jr., Moellering RC, Jr., Novick RP,
et al. (2005) Reduced susceptibility of Staphylococcus aureus to vancomycin and
platelet microbicidal protein correlates with defective autolysis and loss of
accessory gene regulator (agr) function. Antimicrob Agents Chemother 49:
2687–2692.
25. Sakoulas G, Eliopoulos GM, Moellering RC, Jr., Wennersten C,
Venkataraman L, et al. (2002) Accessory gene regulator (agr) locus in
geographically diverse Staphylococcus aureus isolates with reduced susceptibility
to vancomycin. Antimicrob Agents Chemother 46: 1492–1502.
26. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose
vancomycin therapy for methicillin-resistant Staphylococcus aureus infections:
efficacy and toxicity. Arch Intern Med 166: 2138–2144.
27. Holmes N, Turnidge J, Korman T, Munckhof W, O’Sullivan M, et al. (2010)
Increased mortality in patients with Staphylococcus aureus bacteraemia (SAB)
with elevated vancomycin MIC regardless of antibiotic treatment. ISSSI Bath,
United Kingdom, Proffered Paper.
28. Moise PA, Sakoulas G, Forrest A, Schentag JJ (2007) Vancomycin in vitro
bactericidal activity and its relationship to efficacy in clearance of methicillin-
resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51:
2582–2586.
29. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., et al.
(2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin
for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin
Microbiol 42: 2398–2402.
30. Jones RN (2006) Microbiological features of vancomycin in the 21st century:
minimum inhibitory concentration creep, bactericidal/static activity, and
applied breakpoints to predict clinical outcomes or detect resistant strains. Clin
Infect Dis 42 Suppl 1: S13–24.
31. Clinical Laboratory Standards Institute (CLSI) (2010) Performance standards for
antimicrobial susceptibility testing; sixteenth informational supplement. CLSI
document M100-S20. WaynePA: CLSI.
32. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, et al. (2001)
Evaluation of current methods for detection of staphylococci with reduced
susceptibility to glycopeptides. J Clin Microbiol 39: 2439–2444.
33. Walsh TR, Howe RA, Wootton M, Bennett PM, MacGowan AP (2001)
Detection of glycopeptide resistance in Staphylococcus aureus. J Antimicrob
Chemother 47: 357–358.
34. Lesens O, Methlin C, Hansmann Y, Remy V, Martinot M, et al. (2003) Role of
comorbidity in mortality related to Staphylococcus aureus bacteremia: a
prospective study using the Charlson weighted index of comorbidity. Infect
Control Hosp Epidemiol 24: 890–896.
35. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition
of health care-associated infection and criteria for specific types of infections in
the acute care setting. Am J Infect Control 36: 309–332.
hVISA
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21217